AWHL.US Aspira Women's Health Inc.
- Market cap
- USD 8.86M
- P/E
- -
- P/B
- 5.02x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AWHL.US undervalued?
Graham numberThe Graham number of Aspira Women's Health Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aspira Women's Health Inc. fundamental analysis
No fundamental analysis for Aspira Women's Health Inc. yet.
Aspira Women's Health Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign…
Full company profileAspira Women's Health Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aspira Women's Health Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 6.81M | 8.18M | 9.15M | 9.18M | 9.22M | 8.03M |
| Gross Profit | 3.06M | 4.32M | 5.26M | 5.48M | 5.92M | 4.40M |
| Operating Income | -32.6M | -31.1M | -18.9M | -16.3M | -7.91M | -8.08M |
| EBITDA | - | -30.9M | -18.7M | -13.0M | -12.6M | -2.41M |
| Net Income | -31.7M | -29.9M | -16.7M | -13.1M | -12.8M | -3.49M |
| EPS | -4.24 | -3.60 | -1.57 | -0.75 | -0.29 | -0.07 |
| Balance Sheet | ||||||
| Total Assets | 41.1M | 17.4M | 6.26M | 5.49M | 5.46M | 4.44M |
| Total Liabilities | 10.9M | 10.4M | 8.63M | 8.05M | 12.4M | 11.7M |
| Shareholders' Equity | 30.2M | 6.98M | -2.37M | -2.56M | -6.93M | -7.26M |
| Cash & Short-term Investments | 37.2M | 13.3M | 2.60M | 1.77M | 1.76M | 477K |
| Cash Flow | ||||||
| Operating Cash Flow | -27.4M | -31.1M | -15.9M | -12.1M | -7.03M | -4.74M |
| Capital Expenditure | 184K | 232K | 24.0K | 37.0K | 401K | 0.00 |
| Free Cash Flow | -27.6M | -31.3M | -15.9M | -12.2M | -7.43M | -5.04M |
| Ratios | ||||||
| ROE | -104.9% | -428.2% | - | - | - | - |
| ROA | -77.1% | -172.0% | -266.5% | -238.5% | -234.2% | -78.6% |
| Net Profit Margin | -464.8% | -365.2% | -182.3% | -142.6% | -138.7% | -43.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aspira Women's Health Inc. dividends
Aspira Women's Health Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:15 on May 12, 2023.
Who owns Aspira Women's Health Inc.
- Insiders 11.86%
- Institutions 0.81%
- Public & others 87.33%
- Shares outstanding 46.6M
- Free float 39.9M
Aspira Women's Health Inc. company profile
- Company name
- Aspira Women's Health Inc.
- Ticker
- AWHL.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 36
- Fiscal year end
- December
- Address
- Building III, Austin, TX, United States, 78738
- Phone
- 512 519 0400
- Website
- aspirawh.com
About Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; and ENDOinform a multi-marker test program that combines serum proteins, proprietary miRNAs, and clinical data (metadata), for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force; Aspira Synergy platform; and with marketing and distribution agreements. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz; and a strategic alliance agreement with Quest Diagnostics Incorporated and The Cleveland Clinic Foundation. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
Aspira Women's Health Inc. management
6- Mr. John R. Strahley CPACFO & Chief Accounting Officer · born 1968
- Dr. Todd Pappas Ph.D.Chief Science Officer
- Ms. Michelle SniderSenior Vice President of Commercialization & Innovation
- Ms. Jamie L. SullivanChief of Staff & ARPA-H Program Director
- Mr. Matt RameySenior VP of Commercial Operations & Corporate Accounts
- Julie CarrilloCorporate Controller